No one wants to miss a cancer.
Clinical studies of the Imagio® Breast Imaging System have demonstrated:
- Greater confidence in determining whether a mass is benign or malignant1
- Increased specificity to more than 50 percent2, with no significant loss of sensitivity
- Better visualization of presence, absence and morphology of tumor neoangiogenesis than mammography or CDU
Current diagnostic workflow3
Higher confidence creates simplified and streamlined clinical pathways.
On average, 70-80% of biopsies are false positive — wasting precious resources and increasing patient anxiety. Imagio® has the potential to reverse the negative biopsy ratio without missing cancer. Imagio® has the potential to bypass many of the additional, inconclusive exams to reach a definitive diagnosis.
AI-based decision support
Accurately assign diagnostic BI-RADS
Proven to make clinicians more accurate, our proprietary SenoGram® provides AI-driven decision support in assessing likelihood of malignancy (LOM) using 15 different features, integrating clinical, OA/US, mammographic, and sonographic data.5
View SenoGram® brochure Interact with SenoGram®
Our nationwide roadshow can bring Imagio® to your facility or you can start the conversation with a Seno rep today to get more details.
References
- Results from MAESTRO Study of BI-RADS 4a and 4b.
- Results from Reader-02 Study.
- Vlahiotis A, Griffin B, Stavros AT, Margolis J. Analysis of Utilization Patterns and Associated Costs of the Breast Imaging and Diagnostic Procedures After Screening Mammography. ClinicoEconomics and Outcomes Research 2018:10 157-167.
- EUSOBI 2022 Interim CONFIDENCE Registry Results.
- Seiler SJ, Neuschler EI, Butler RS, Lavin PT, Dogan BE. Optoacoustic imaging with decision support for differentiation of benign and malignant breast masses: A 15-reader retrospective study. AJR Am J Roentgenol. December 7, 2022.